EPO vs MGF (Mechano Growth Factor)
A side-by-side research comparison of EPO and MGF (Mechano Growth Factor) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | EPO | MGF (Mechano Growth Factor) |
|---|---|---|
| Full name | Erythropoietin (EPO) | Mechano Growth Factor (IGF-1Ec splice variant) |
| Category | Muscle Growth | Muscle Growth |
| Status | FDA-approved drug (prescription) | Research compound |
| Mechanism | Binds erythropoietin receptors on bone marrow progenitor cells, stimulating proliferation and maturation of red blood cells. More red cells raise oxygen-carrying capacity, but also thicken the blood. | Unique E-domain activates quiescent satellite cells for proliferation. Distinct from IGF-1Ea which drives differentiation. PEGylated form extends short half-life. |
| Molecular weight | ~34 kDa (glycosylated) | 2,867 Da (synthetic fragment) |
| Half-life | ~4-13 hours (varies by formulation) | 5-7 min (native) / 24-48h (PEGylated) |
| Bioavailability | Subcutaneous or intravenous injection | High (local IM) |
| Typical dose | Prescription-only, condition-specific | 100-200 mcg PEG-MGF |
| Frequency | Per medical protocol | 2-3x per week |
| Route | Subcutaneous or IV injection | Intramuscular (local) |
EPO reported benefits
- Increases red blood cell production
- Treats anemia (medical use)
- Raises oxygen-carrying capacity
MGF (Mechano Growth Factor) reported benefits
- Satellite cell activation
- Muscle-specific growth
- Repair response enhancement
- Synergistic with training
- Local hypertrophy
Related comparisons
Research and educational reference only. Not medical advice.